first paper in this series discusses drug-induced taste disorders (DITD). Fark, Hummel, Hahner, Nin, and Hummel (2013) divided taste disorders into quantitative taste disorders and qualitative taste disorders. Quantitative taste disorders include hypergeusia (an abnormally heightened sense of taste), normogeusia (a normal sense of taste), hypogeusia (an abnormally lowered sense of taste), and ageusia (a lacking sense of taste). Qualitative taste disorders are dysgeusia (a distortion in sense taste) and phantogeusia (a taste perception without a stimulus) (Fark et al., 2013) . Although disturbances in taste seem harmless, they can interfere with a patients' social behavior by avoiding dinners or lead to a change in diet which can, among others, cause weight loss, nutrient deficiencies, or overweight due to excessive use of salt and sugar to compensate bad flavors (Noel, Sugrue, & Dando, 2017) . As such, taste disorders can lead to a significant reduction in the quality of life (Ponticelli et al., 2017) . Therefore, it is important that oral healthcare professionals are aware of the possible causes and treatment modalities of taste disorders. Adverse effects of drugs account for 9%-22% of the taste disorders (Fark et al., 2013; Hamada, Endo, & Tomita, 2002) . This article aims to support oral healthcare professionals in their decision making whether a taste disorder can be due to use of drugs by providing a comprehensive overview of drugs documented with taste disorders as an adverse effect.
| MATERIAL S AND ME THODS

| Data source
The Informatorium Medicamentorum (IM) of the Royal Dutch Pharmacists Association (KNMP) is the leading national drug information database and reference work for pharmacists in the Netherlands.
This database is based on scientific drug information, guidelines, and summaries of product characteristics (SmPCs) (KNMP, 2019) . The IM is updated every 2 weeks with the latest available information from scientific publications, warnings of authorities, and SmPCs of the European Medicines Agency and Medicines Evaluation Board in the Netherlands.
The IM was last searched on August 1, 2018, and all data regarding adverse effects available that time were included in this study. Of each drug, the category "side effects" from the IM was searched for taste disorders and synonyms (e.g., dysgeusia).
The following characteristics of drugs causing DITD were registered: generic name of the drug, term of the adverse effect, incidence of the adverse effect, and Anatomic Therapeutical Chemical (ATC) codes of the drug. The ATC classification was developed by the World Health Organization and categorizes all active substances in drugs according to a hierarchy with five levels. It serves as a tool for exchanging data on drug use on a national and international level (WHO, 2003) .
It is worth noting that one active substance can be used in different drugs with different treatment goals. Therefore, it is possible that one active substance (e.g., miconazole) has several ATC codes ( Figure 1) .
Originally, the terms used to describe one adverse effect (e.g., taste disorders) in the SmPCs varied between drugs and throughout the years. In order to create a standardized structured database, the MedDRA classification was manually applied after the selection of drugs causing DITD. The MedDRA classification is developed by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human and endeavors to standardize all international medical terminology, including terms for adverse effects (Meddra, 2019) . The MedDRA classification is a hierarchical system that distinguishes five levels in the categorization of medical terminology. The most specific level is the "Lowest Level Term (LLT)" and the next level is called the "Preferred Term (PT)." Each LLT is directly linked to only one PT. Each PT is linked to at least one LLT (itself) and sometimes several synonyms of the LLT. In Figure 2 , the PT "Hypogeusia" is presented with its LLTs. After the selection of drugs related to DITD from the IM, the adverse effect terms were first matched F I G U R E 1 Hierarchy of ATC levels for miconazole [Colour figure can be viewed at wileyonlinelibrary.com] in accordance with the support document (Meddra, 2018) , with the most applicable LLT in Dutch. Terms were then translated into English by using the LLT codes and the English version of MedDRA.
The English LLT was automatically matched with the English PT level according to the MedDRA hierarchy.
Microsoft® Excel (version 16.16.1) was used to create the database with the acquired information on DITD and to perform descriptive statistics.
| RE SULTS
In total, 1,645 drugs (active substances) were registered in the IM.
Each drug can cause multiple adverse effects resulting in approximately 65,000 unique combinations between a drug and an adverse effect in the IM. Of these 65,000 combinations, 2,335 (3.5%) were defined by the authors as relevant for the oral healthcare provider and 343 (0.5%) concerned taste disorders. Of the 1,645 drugs, 314 (19%) could cause DITD. As IM discriminates different administration forms per drug, the number of drugs (314) and number of combinations (343) causing taste disorders differ. For example, "Budesonide," which can be administered rectally, nasally, and by inhalation, is registered three times with dysgeusia as a potential adverse effect with three different incidences. Table 1 presents the different LLTs and PTs used in the IM for taste disorders and the number drugs which can potentially cause them. Taste disturbance as an adverse effect was reported in all level 1 categories of the ATC classification (Table 2) . "Normogeusia," "hypergeusia," "ageusia," and "phantogeusia"
were not reported in the IM.
| Dysgeusia
Dysgeusia (PT) as an adverse effect was reported 282 times (17.1% of 1,645 drugs) ( Table 1 ). The drug categories "antineoplastic and immunomodulating agents" (18.8%), "antiinfectives for systemic use" (15.6%), and "nervous system" (13.8%) account for almost half of the drug-induced dysgeusia (Table 2) . Hypergeusia, ageusia, and phantogeusia were not reported. Table 3 presents a selection of the drugs that could cause dysgeusia (PT) and comprises only the category "Alimentary tract and metabolism." The frequencies of the adverse effect and whether a drug also causes the adverse effects "parosmia," "anosmia," "dry mouth," or "hyposalivation" are presented as well, since these adverse effects are closely related to taste disorders. In some drugs, dysgeusia is only caused when the drug is administered through a specific route or under certain circumstances. The full table of all the 282 drugs causing dysgeusia is presented online as supplementary data (Table S1 ).
In these 282 drugs, the frequency of dysgeusia was "very common" in 7.1%, "common" in 31.2%, "uncommon" in 32.7%, and "rare or very rare" in 9.9% of the drugs. In 19.1% of the drugs, the "frequency was not known," which means that in the IM, the frequency could not be estimated based on the available data.
Dysgeusia coincided in 114/282 drugs (40.4%) with "dry mouth"
as an adverse effect, in 5/282 drugs (1.7%) with "anosmia," in 2/282 F I G U R E 2 Hierarchy of "Hypogeusia" in MedDRA [Colour figure can be viewed at wileyonlinelibrary.com]
TA B L E 1 LLTs and PT for taste disorders in IM analysis
Adverse effect term
No. of drugs
Taste bitter (LLT) 9
Taste disturbance (LLT) 245
Taste garlic (LLT) 1
Taste metallic (LLT) drugs (0.7%) with "parosmia," in 6/282 drugs (2.1%) with "dry mouth and anosmia," and in 3/282 drugs (1.0%) with "dry mouth and parosmia." None of these drugs were reported to cause "hyposalivation." Tables S2 and S3 present drugs that cause a bitter taste (LLT) or metallic taste (LLT), respectively. Disulfiram (N07BB01), a drug used to treat patients with alcohol abuses, was the only drug reported to cause a garlic taste (LLT).
Supplementary online
| Hypogeusia
Drug-induced hypogeusia was reported in 61 drugs (3.7% of 1,645).
Hypogeusia was predominantly reported in the drug categories "Antineoplastic and immunomodulating agents" (39.0%) and
"Nervous system" (19%). Hypogeusia did not occur in the drug categories "Respiratory system" and "Antiparasitic products, insecticides and repellents" (Table 2) . Table 4 presents all drugs in the IM that are reported to cause hypogeusia. In these 61 drugs, the frequency of hypogeusia was "very common" in 9.5%, "common" in 31.7%, "uncommon" in 25.4%, and "rare or very rare" in 15.9% of the drugs. In 17.5% of the drugs, the "frequency was not known." Hypogeusia coincided in 28/61 drugs (45.9%) with "dry mouth," in 1/61 drugs (1.6%)
with "anosmia," and in 2/61 drugs (3.2%) with "dry mouth/anosmia."
None of these drugs were reported to cause "hyposalivation."
| D ISCUSS I ON
In total, 20% (343/1,645) of the drugs used in the Netherlands has been reported to potentially cause DITD (dysgeusia and hypogeusia).
DITD was reported in all ATC level 1 categories, suggesting that all healthcare professionals may frequently encounter the adverse effects of these drugs. Healthcare professionals that treat patients using antineoplastic drugs are most likely to be confronted with DITD. Despite the recorded percentage of our search, the exact incidence of DITD is unclear due to a lack of systematic well controlled clinical trials (Schiffman, 2018) .
To the best of our knowledge, this study is the first compre- Our data source contains predominantly PT level terms. Although this is in accordance with the MedDRA guidelines, it is likely that specific LLT terms like "bitter taste" and "metallic taste" might therefore be underreported compared to previous studies which do not use the MedDRA. It also has to be mentioned that the terms and incidences used in the database (e.g., "dysgeusia", "hypoguesia") are based on patient-reported adverse effects during pharmacological developing studies or postmarketing studies. This subjective reporting by patients Antiparasitic products, insecticides, and repellents 5 (1.7)
-5
Blood and blood forming organs 13 (4.6) 1 (1.4) 14
Cardiovascular system 23 (8.1) 5 (7.8) 28
Dermatologicals 13 (4.6) 2 (3.2) 15
Genitourinary system and sex hormones 5 (1.7) 3 (4.7) 8
Musculoskeletal system 12 (4.3) 2 (3.1) 14
Nervous system 39 (13.8) 12 (19.0) 51
Respiratory system 16 (5.7) -16
Sensory organs 10 (3.5) 1 (1.5) 10
Systemic hormonal preparations, excl. might lead to a reporting bias or inaccuracy in terminology. The difference between objective and subjective adverse effects measuring is a common point of discussion when reporting on adverse effects and one without a clear solution. When considering taste disorders, there is no commonly used test available for objectifying taste disorders, which makes it impossible to report solely objective data. In order to make future studies on oral adverse effects more comparable, it is recommended that the MedDRA terminology and hierarchy and, if available, objective tests are used during data collection and describing the results. Homogenous reporting of results, on for instance incidences, will lead to clinically more applicable data. Due to differences in local and regional laws and regulations on drug admission, registered drugs differ per country. Thus, there will be drugs that are reported in the current study that are not available in some countries and reverse. However, with regard to the European countries, most of the reported drugs will be available in all countries. By applying the ATC and MedDRA classification, the data are internationally applicable and could serve as a guidance for future reports on DITD.
The exact mechanisms underlying DITD are still unclear and may vary between individuals. Individual variations may be caused by polypharmacy (drug interactions), dosage differences, and patient-specific variables (e.g., genetics, age, and medical conditions) (Schiffman, 2018) . Schiffman (2018) describes several presumed mechanisms behind DITD. Some drugs have sensory properties that cause a bitter or metallic taste. These drugs interact with the taste buds: (a) after oral application, (b) by diffusion into the saliva after absorption in the gut or intravenous administration, or (c) by accumulation in the taste buds when used chronically. The latter might explain why DITD can occur months or years after the initial usage (e.g., lithium carbonate). Other drugs distort taste and smell signals for sweet or salt, causing a bitter or sour taste perception of food and beverages. The garlic-like taste caused by disulfiram is due to exhalation of carbon disulfide. Drugdrug interactions can lead to elevated blood plasma levels beyond therapeutic concentrations and therefore cause DITD, which particularly could occur in polypharmacy patients.
Saliva could also play a role in the underlying mechanism of DITD.
Saliva protects the external environment of the taste receptor cells and acts as a solvent and transportation medium for taste substances (Matsuo, 2000) . Many drugs are known to cause quantitative or qualitative changes in saliva (Wolff et al., 2017) . Almost 45% of the drugs known to potentially cause DITD coincided with dry mouth as an adverse effect, suggesting that there is at least some correlation. However, the exact correlation is difficult to assess since both MedDRA and the data that underlie the IM do not clearly discriminate between subjective "xerostomia" and objective "hyposalivation." The term "dry mouth" is presumably used for both.
A healthcare professional confronted with a patient with DITD should assess which drug, or drug combination, is presumably responsible for the DITD. This can be done by comparing the temporal onset of DITD with the alterations in the drug usage (e.g., dosage, new drugs). However, as stated before, it is possible that DITD occurs months or years after the initial usage, complicating TA B L E 4 (Continued)
the assessment of a temporal relationship. Another possibility is to consult pharmaceutical databases and overviews like the approach used in the present study.
Cessation of the drug responsible for DITD will most likely result in a decrease and eventually even recovery of DITD, but this (partial) recovery could take months. If cessation and alterations are not possible, other treatment modalities could be considered to relieve the symptoms. The evidence behind these modalities is scarce and based on research on taste disorders with other causes than DITD.
Proposed treatment modalities include improving oral hygiene, suppletion of zinc, stimulation food flavors, saliva substitutes, and administration of alpha lipoic acid (Briggs, 2009; Femiano, Scully, & Gombos, 2002; Kumbargere Nagraj et al., 2017; Schiffman, 2018) .
| CON CLUS ION
Healthcare professionals are frequently confronted with drugs that are documented with DITD. The exact incidences of DITD remain unclear. This overview supports clinicians in their awareness, diagnosis, and possible treatment of DITD, and could serve as a reference for future research reporting on DITD.
